- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Prelude Therapeutics prices $90M equity offering | 1 | Seeking Alpha | ||
| PRELUDE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mo | Prelude Therapeutics, Incorporated: Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering | 1 | GlobeNewswire (USA) | ||
| Mo | Prelude Therapeutics presents preclinical data on breast cancer drug | 1 | Investing.com | ||
| Mo | Prelude Therapeutics, Incorporated: Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research ... | 4 | GlobeNewswire (USA) | ||
| 15.04. | Prelude Therapeutics, Incorporated: Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer | 296 | GlobeNewswire (Europe) | WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) ("Prelude Therapeutics" or the "Company"), a clinical-stage precision oncology company, today... ► Artikel lesen | |
| 15.04. | Prelude Therapeutics Inc - 8-K, Current Report | - | SEC Filings | ||
| 17.03. | Prelude Therapeutics, Incorporated: Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 12.03. | Prelude Therapeutics plant Aktienemission im Wert von bis zu 25 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 11.03. | Potenzial bei Blutkrankheiten: Citizens verdoppelt Kursziel für Prelude Therapeutics | 1 | Investing.com Deutsch | ||
| 11.03. | Citizens raises Prelude Therapeutics price target on JAK2 potential | 1 | Investing.com | ||
| 10.03. | Prelude Therapeutics Inc - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 10.03. | Prelude Therapeutics Inc - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.03. | Prelude Therapeutics Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 10.03. | Prelude Therapeutics Earnings Report: Q4 Overview | 3 | Benzinga.com | ||
| 10.03. | Prelude Therapeutics GAAP EPS of -$1.29 misses by $0.04, revenue of $12.14M | 1 | Seeking Alpha | ||
| 10.03. | Prelude Therapeutics, Incorporated: Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 | 150 | GlobeNewswire (Europe) | Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with polycythemia... ► Artikel lesen | |
| 04.02. | Prelude Therapeutics stock gets reiterated Market Outperform rating at Citizens | 1 | Investing.com | ||
| 03.02. | Prelude Therapeutics Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 03.02. | Prelude Therapeutics, Incorporated: Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor | 200 | GlobeNewswire (Europe) | WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, today announced that the U.S. Food and Drug Administration (FDA)... ► Artikel lesen | |
| 09.01. | Prelude Therapeutics Inc - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,00 | -0,44 % | Nahost-Konflikt belastet Märkte: Food-Lieferketten werden zum Schlüsselthema - MustGrow, K+S, Evotec und BioNTech im Fokus | Der Nahost-Konflikt rückt die globalen Lieferketten erneut in den Fokus und erhöht den Druck auf sensible Versorgungswege. Besonders die Straße von Hormus bleibt dabei ein zentraler geopolitischer Risikofaktor... ► Artikel lesen | |
| EVOTEC | 5,225 | -3,24 % | Evotec Aktie erholt sich kräftig: 200-Tage-Linie wieder der Partykiller? | Die Evotec Aktie hat sich in den vergangenen Tagen spürbar erholt und notiert auf XETRA bei 5,570 Euro, ein leichtes Plus von 0,45 Prozent. Vom Baissetief bei 3,996 Euro hat der Titel damit zwischenzeitlich... ► Artikel lesen | |
| MODERNA | 45,490 | +0,64 % | Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April... ► Artikel lesen | |
| AMGEN | 296,10 | -0,75 % | Amgen Announces Retirement Of David M. Reese, Executive Vice President And Chief Technology Officer | Organizational Changes Further Emphasize Integration of Biology and Technology
THOUSAND OAKS, Calif., April 22, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced... ► Artikel lesen | |
| NOVAVAX | 6,990 | +0,29 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| BIOFRONTERA | 2,520 | -0,79 % | Biofrontera: 2025 war ein richtungsweisendes Jahr | Leverkusen (www.anleihencheck.de) - Biofrontera: 2025 war ein richtungsweisendes Jahr - AnleihenewsAnbei eine aktuelle Pressemitteilung der Biofrontera AG (ISIN DE000A4BGGM7/ WKN A4BGGM)- Im dritten... ► Artikel lesen | |
| BIOXXMED | 0,905 | 0,00 % | PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH | DJ PTA-News: bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Vollzug des Verkaufs der Rancoderm GmbH
Heidelberg (pta000/09.03.2026/13:50... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,550 | +1,60 % | Better Long-Term Buy: Eli Lilly or Viking Therapeutics? | ||
| DEFENCE THERAPEUTICS | 0,324 | -3,57 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Warrant Terms Amendment | Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,400 | +1,27 % | NurExone: US-Offensive nimmt Form an | ||
| ABIVAX | 97,70 | 0,00 % | EQS-News: ABIVAX: Abivax to Present Data on Obefazimod at Digestive Disease Week | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax to Present Data on Obefazimod at Digestive Disease Week
22.04.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| IBIO | 1,518 | -2,25 % | iBio, Inc.: iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia | IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst participants expected to be dosed in 2Q 2026 SAN... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 64,46 | +1,22 % | Arrowhead upgraded at Morgan Stanley on upcoming catalysts | ||
| TME PHARMA | 0,075 | +27,55 % | TME Pharma NV: TME Pharma Announces Publication of NOX-A12 "Triple Therapy" Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications | TME Pharma Announces Publication of NOX-A12 "Triple Therapy" Phase 1/2 Expansion Arm A Findings from GLORIA trial in Nature Communications Berlin, Germany, April 16, 2026, 08.00am CET - TME Pharma... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,520 | +1,79 % | Voyager Therapeutics CFO resigns; Robin Swartz takes financial charge |
Das Unternehmen PRELUDE THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,410 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRELUDE THERAPEUTICS INC finden Sie auf Wallstreet Online.